Cargando…
Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors
Dysregulation of the cell cycle and cyclin-dependent kinases (cdks) is a hallmark of cancer cells. Intervention with cdk function is currently evaluated as a therapeutic option in many cancer types including neuroblastoma (NB), a common solid tumor of childhood. Re-analyses of mRNA profiling data fr...
Autores principales: | Schwermer, Melanie, Lee, Sangkyun, Köster, Johannes, van Maerken, Tom, Stephan, Harald, Eggert, Angelika, Morik, Katharina, Schulte, Johannes H., Schramm, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558161/ https://www.ncbi.nlm.nih.gov/pubmed/26029996 |
Ejemplares similares
-
Robust Selection of Cancer Survival Signatures from High-Throughput Genomic Data Using Two-Fold Subsampling
por: Lee, Sangkyun, et al.
Publicado: (2014) -
Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma
por: Rihani, Ali, et al.
Publicado: (2015) -
RITA displays anti-tumor activity in medulloblastomas independent of TP53 status
por: Gottlieb, Aline, et al.
Publicado: (2017) -
Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells
por: Pajtler, Kristian W., et al.
Publicado: (2014) -
The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models
por: Pajtler, Kristian W, et al.
Publicado: (2016)